MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
56.72
+2.30
+4.23%
Pre Market: 56.62 -0.1 -0.18% 06:31 01/08 EST
OPEN
55.24
PREV CLOSE
54.42
HIGH
56.74
LOW
55.23
VOLUME
17
TURNOVER
--
52 WEEK HIGH
60.28
52 WEEK LOW
41.88
MARKET CAP
115.47B
P/E (TTM)
19.15
1D
5D
1M
3M
1Y
5Y
1D
Is Bristol Myers Squibb (BMY) Quietly Recasting Its Post-Patent Story With Opdivo And KarXT Moves?
Simply Wall St · 6h ago
3 Drug Stocks to Buy at a Discount
The Motley Fool · 15h ago
Bristol-Myers Squibb Is Maintained at Neutral by Citigroup
Dow Jones · 16h ago
Bristol-Myers Squibb Price Target Raised to $53.00/Share From $45.00 by Citigroup
Dow Jones · 16h ago
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Benzinga · 17h ago
Bristol-Myers Squibb Targets Autism Irritability With New Phase 3 Trial, Expanding Its Neuroscience Reach
TipRanks · 20h ago
Bristol-Myers Squibb Quietly Expands Pipeline With New First-in-Human Study of BMS-986521
TipRanks · 20h ago
Bristol-Myers Squibb’s Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story
TipRanks · 20h ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.